Skip to main content

LMNA KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 4 and 1 bp deletion in exon 4 and 22 bp deletion in exon 4.

Be the first to review this product! Submit a review

Images

Western blot - Human LMNA (Lamin A) knockout HeLa cell line (AB261787), expandable thumbnail
  • Western blot - Human LMNA (Lamin A) knockout HeLa cell line (AB261787), expandable thumbnail
  • Sanger Sequencing - Human LMNA (Lamin A) knockout HeLa cell line (AB261787), expandable thumbnail
  • Sanger Sequencing - Human LMNA (Lamin A) knockout HeLa cell line (AB261787), expandable thumbnail
  • Sanger Sequencing - Human LMNA (Lamin A) knockout HeLa cell line (AB261787), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 4 and 1 bp deletion in exon 4 and 22 bp deletion in exon 4

Alternative names

70 kDa lamin, CDDC, EMD2, FPL, FPLD, HGPS, IDC, LAMIN A, LAMIN C, LDP1, LFP, LMN 1, LMN C, LMNA_HUMAN, Lamin-A/C, PRO1, Renal carcinoma antigen NY-REN-32

Recommended products

LMNA KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 4 and 1 bp deletion in exon 4 and 22 bp deletion in exon 4.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 4 and 1 bp deletion in exon 4 and 22 bp deletion in exon 4
Antibiotic resistance
Puromycin 1µg/mL
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
LMNA
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Lamin A also known as LMNA is a type of lamin protein integral to the nuclear architecture. It has a molecular weight of approximately 70 kDa. This protein localizes mainly to the nuclear lamina a dense fibrillar network inside the inner nuclear membrane found across various cell types. Lamin A serves as a structural scaffold mediating nuclear stability and rigidity. It also plays a role in chromatin organization supporting overall nuclear functions.

Biological function summary

The lamin molecule interacts with several nuclear components forming part of the nuclear lamina complex. It anchors chromatin material and regulates DNA replication and repair. Lamin A protein also modulates gene expression through interactions with transcription factors. Beyond structural support it influences cell cycle progression and differentiation impacting cellular mechanotransduction and signaling processes.

Pathways

Lamin A performs critical functions within the cell cycle and apoptotic pathways. Its interactions with the retinoblastoma protein (pRB) and other cyclin-dependent kinases control cell cycle checkpoints and progression. Moreover lamin A connects with proteins involved in signaling pathways like MAPK which relate to stress responses and cellular growth. These interactions highlight its dynamic involvement in maintaining cell health and proliferation.

Associated diseases and disorders

Mutations in the lamin A gene associate closely with Hutchinson-Gilford Progeria Syndrome and Emery-Dreifuss Muscular Dystrophy. In these conditions altered lamin A protein affects nuclear shape and chromatin layout disrupting transcriptional regulation. The mutated lamin A protein interacts differently with binding partners like emerin contributing to muscle adipose tissue and multi-system abnormalities. This highlights the critical role lamin A plays in maintaining normal cellular function across life stages.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

5 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com